Intas Pharmaceuticals Ltd. Announces Licensing Agreement with mAbxience, for an Etanercept Biosimilar Targeting Autoimmune Diseases in more than 150 Countries, including Europe and the United States of America
Intas gains exclusive commercialization rights for the Etanercept biosimilar, for more than 150 countries worldwide.This collaboration with mAbxience strengthens the ...
Read more